Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

Andreas G. Tzakis, Tomoaki Kato, Seigo Nishida, David M. Levi, Juan R. Madariaga, Jose R. Nery, Naveen Mittal, Arie Regev, G. Patricia Cantwell, Anthony Gyamfi, Debbie Weppler, Joshua Miller, Panagiotis Tryphonopoulos, Phillip Ruiz

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background. The aim of this research was to study the efficacy of campath 1H in combination with lowdose tacrolimus immunosuppression for intestinal, multivisceral, and liver transplantation. Methods. Campath 1H (0.3 mg/kg) was administered in four doses: Preoperatively, at the completion of the transplant, and on postoperative days 3 and 7. Tacrolimus levels were maintained between 5 to 10 ng/dL. Suspected or mild rejections were treated with steroids. Moderate or severe rejections were treated with OKT3. Patients. We studied three groups of patients: adult recipients of intestinal or multivisceral transplants, high-risk pediatric recipients of small-bowel or multivisceral grafts, and adult liver-transplant recipients. Results. Twenty-one adult intestinal recipients received 24 grafts. With follow-up of 2.4 to 16 months, 14 patients are alive and 14 grafts are functioning. Eleven high-risk pediatric intestinal recipients received 12 grafts. There were four mortalities in this group, and after a follow up of 1 to 8.5 months, four patients have not experienced a rejection episode. Five adult liver recipients received five grafts. With a follow-up of 3 to 6.2 months, all five patients are alive. There were no rejection episodes in this group, and none of them required steroid therapy. Conclusions. This immunosuppressive regimen allows for the avoidance of maintenance adjuvant-steroid treatment in the majority of our patients. Our preliminary data show a trend toward a reduction of the incidence and the severity of rejection episodes, although we need to follow-up larger numbers of patients to confirm these results.

Original languageEnglish
Pages (from-to)1227-1231
Number of pages5
JournalTransplantation
Volume75
Issue number8
DOIs
StatePublished - Apr 27 2003

Fingerprint

Liver Transplantation
Transplants
Steroids
Tacrolimus
Pediatrics
Muromonab-CD3
Liver
Immunosuppressive Agents
alemtuzumab
Immunosuppression
Maintenance
Mortality
Incidence
Therapeutics
Research

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Tzakis, A. G., Kato, T., Nishida, S., Levi, D. M., Madariaga, J. R., Nery, J. R., ... Ruiz, P. (2003). Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation, 75(8), 1227-1231. https://doi.org/10.1097/01.TP.0000065192.53065.50

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. / Tzakis, Andreas G.; Kato, Tomoaki; Nishida, Seigo; Levi, David M.; Madariaga, Juan R.; Nery, Jose R.; Mittal, Naveen; Regev, Arie; Patricia Cantwell, G.; Gyamfi, Anthony; Weppler, Debbie; Miller, Joshua; Tryphonopoulos, Panagiotis; Ruiz, Phillip.

In: Transplantation, Vol. 75, No. 8, 27.04.2003, p. 1227-1231.

Research output: Contribution to journalArticle

Tzakis, AG, Kato, T, Nishida, S, Levi, DM, Madariaga, JR, Nery, JR, Mittal, N, Regev, A, Patricia Cantwell, G, Gyamfi, A, Weppler, D, Miller, J, Tryphonopoulos, P & Ruiz, P 2003, 'Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation', Transplantation, vol. 75, no. 8, pp. 1227-1231. https://doi.org/10.1097/01.TP.0000065192.53065.50
Tzakis AG, Kato T, Nishida S, Levi DM, Madariaga JR, Nery JR et al. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation. 2003 Apr 27;75(8):1227-1231. https://doi.org/10.1097/01.TP.0000065192.53065.50
Tzakis, Andreas G. ; Kato, Tomoaki ; Nishida, Seigo ; Levi, David M. ; Madariaga, Juan R. ; Nery, Jose R. ; Mittal, Naveen ; Regev, Arie ; Patricia Cantwell, G. ; Gyamfi, Anthony ; Weppler, Debbie ; Miller, Joshua ; Tryphonopoulos, Panagiotis ; Ruiz, Phillip. / Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. In: Transplantation. 2003 ; Vol. 75, No. 8. pp. 1227-1231.
@article{539acc9d9e2c4017be69921987d62367,
title = "Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation",
abstract = "Background. The aim of this research was to study the efficacy of campath 1H in combination with lowdose tacrolimus immunosuppression for intestinal, multivisceral, and liver transplantation. Methods. Campath 1H (0.3 mg/kg) was administered in four doses: Preoperatively, at the completion of the transplant, and on postoperative days 3 and 7. Tacrolimus levels were maintained between 5 to 10 ng/dL. Suspected or mild rejections were treated with steroids. Moderate or severe rejections were treated with OKT3. Patients. We studied three groups of patients: adult recipients of intestinal or multivisceral transplants, high-risk pediatric recipients of small-bowel or multivisceral grafts, and adult liver-transplant recipients. Results. Twenty-one adult intestinal recipients received 24 grafts. With follow-up of 2.4 to 16 months, 14 patients are alive and 14 grafts are functioning. Eleven high-risk pediatric intestinal recipients received 12 grafts. There were four mortalities in this group, and after a follow up of 1 to 8.5 months, four patients have not experienced a rejection episode. Five adult liver recipients received five grafts. With a follow-up of 3 to 6.2 months, all five patients are alive. There were no rejection episodes in this group, and none of them required steroid therapy. Conclusions. This immunosuppressive regimen allows for the avoidance of maintenance adjuvant-steroid treatment in the majority of our patients. Our preliminary data show a trend toward a reduction of the incidence and the severity of rejection episodes, although we need to follow-up larger numbers of patients to confirm these results.",
author = "Tzakis, {Andreas G.} and Tomoaki Kato and Seigo Nishida and Levi, {David M.} and Madariaga, {Juan R.} and Nery, {Jose R.} and Naveen Mittal and Arie Regev and {Patricia Cantwell}, G. and Anthony Gyamfi and Debbie Weppler and Joshua Miller and Panagiotis Tryphonopoulos and Phillip Ruiz",
year = "2003",
month = "4",
day = "27",
doi = "10.1097/01.TP.0000065192.53065.50",
language = "English",
volume = "75",
pages = "1227--1231",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

AU - Tzakis, Andreas G.

AU - Kato, Tomoaki

AU - Nishida, Seigo

AU - Levi, David M.

AU - Madariaga, Juan R.

AU - Nery, Jose R.

AU - Mittal, Naveen

AU - Regev, Arie

AU - Patricia Cantwell, G.

AU - Gyamfi, Anthony

AU - Weppler, Debbie

AU - Miller, Joshua

AU - Tryphonopoulos, Panagiotis

AU - Ruiz, Phillip

PY - 2003/4/27

Y1 - 2003/4/27

N2 - Background. The aim of this research was to study the efficacy of campath 1H in combination with lowdose tacrolimus immunosuppression for intestinal, multivisceral, and liver transplantation. Methods. Campath 1H (0.3 mg/kg) was administered in four doses: Preoperatively, at the completion of the transplant, and on postoperative days 3 and 7. Tacrolimus levels were maintained between 5 to 10 ng/dL. Suspected or mild rejections were treated with steroids. Moderate or severe rejections were treated with OKT3. Patients. We studied three groups of patients: adult recipients of intestinal or multivisceral transplants, high-risk pediatric recipients of small-bowel or multivisceral grafts, and adult liver-transplant recipients. Results. Twenty-one adult intestinal recipients received 24 grafts. With follow-up of 2.4 to 16 months, 14 patients are alive and 14 grafts are functioning. Eleven high-risk pediatric intestinal recipients received 12 grafts. There were four mortalities in this group, and after a follow up of 1 to 8.5 months, four patients have not experienced a rejection episode. Five adult liver recipients received five grafts. With a follow-up of 3 to 6.2 months, all five patients are alive. There were no rejection episodes in this group, and none of them required steroid therapy. Conclusions. This immunosuppressive regimen allows for the avoidance of maintenance adjuvant-steroid treatment in the majority of our patients. Our preliminary data show a trend toward a reduction of the incidence and the severity of rejection episodes, although we need to follow-up larger numbers of patients to confirm these results.

AB - Background. The aim of this research was to study the efficacy of campath 1H in combination with lowdose tacrolimus immunosuppression for intestinal, multivisceral, and liver transplantation. Methods. Campath 1H (0.3 mg/kg) was administered in four doses: Preoperatively, at the completion of the transplant, and on postoperative days 3 and 7. Tacrolimus levels were maintained between 5 to 10 ng/dL. Suspected or mild rejections were treated with steroids. Moderate or severe rejections were treated with OKT3. Patients. We studied three groups of patients: adult recipients of intestinal or multivisceral transplants, high-risk pediatric recipients of small-bowel or multivisceral grafts, and adult liver-transplant recipients. Results. Twenty-one adult intestinal recipients received 24 grafts. With follow-up of 2.4 to 16 months, 14 patients are alive and 14 grafts are functioning. Eleven high-risk pediatric intestinal recipients received 12 grafts. There were four mortalities in this group, and after a follow up of 1 to 8.5 months, four patients have not experienced a rejection episode. Five adult liver recipients received five grafts. With a follow-up of 3 to 6.2 months, all five patients are alive. There were no rejection episodes in this group, and none of them required steroid therapy. Conclusions. This immunosuppressive regimen allows for the avoidance of maintenance adjuvant-steroid treatment in the majority of our patients. Our preliminary data show a trend toward a reduction of the incidence and the severity of rejection episodes, although we need to follow-up larger numbers of patients to confirm these results.

UR - http://www.scopus.com/inward/record.url?scp=0037469040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037469040&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000065192.53065.50

DO - 10.1097/01.TP.0000065192.53065.50

M3 - Article

VL - 75

SP - 1227

EP - 1231

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -